rss
Br J Ophthalmol 2005;89:1171-1175 doi:10.1136/bjo.2004.064477
  • Clinical science
    • Extended reports

A case control study of age related macular degeneration and use of statins

  1. L Smeeth1,
  2. C Cook1,
  3. U Chakravarthy2,
  4. R Hubbard3,
  5. A E Fletcher1
  1. 1Department of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London, United Kingdom
  2. 2Centre for Vision Science, The Queen’s University of Belfast. Institute of Clinical Science, Royal Hospitals, Belfast, UK
  3. 3Division of Respiratory Medicine, University of Nottingham, Nottingham City Hospital, UK
  1. Correspondence to: Dr L Smeeth Department of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, Keppel Street, London WC1E 7HT, UK; liam.smeethlshtm.ac.uk
  • Accepted 8 April 2005

Abstract

Aims: Age related macular degeneration (AMD) is the leading cause of blindness in industrialised countries. Previous studies have suggested that statins may have a protective effect against the disease; however, existing studies have had limited power to reliably detect or exclude an effect and have produced conflicting results. The authors assessed the risk of AMD associated with the use of statins.

Methods: Population based case control study using the United Kingdom General Practice Research Database. 18 007 people with diagnosed AMD were compared with 86 169 controls matched on age, sex, and general practice. The primary outcome was the odds ratio for the association between exposure to statins and AMD.

Results: The crude odds ratio for the association between any recorded exposure to statins and AMD was 1.32 (95% CI 1.17 to 1.48), but this reduced to 0.93 (95% CI 0.81 to 1.07, p = 0.33) after adjustment for consultation rate, smoking, alcohol intake, body mass index, atherosclerotic disease, hyperlipidaemia, heart failure, diabetes mellitus, hypertension, use of other cardiovascular drugs, and use of fibrates. There was no evidence that the risk varied by dose of statin, duration of use, or that the risk varied for individual statins.

Conclusion: In the short and medium term statin use is not associated with a decreased risk of AMD. Whether subgroups of patients with specific forms of AMD (particularly choroidal neovascularisation) benefit from statin therapy remains a possibility.

Footnotes

  • Funding: the study was funded by the United Kingdom Medical Research Council (MRC). Liam Smeeth is supported by a Medical Research Council clinician scientist fellowship. Richard Hubbard is supported by a Wellcome Trust advanced fellowship.

  • Competing interests: none declared

This Article

  1. Abstract
  2. Full text
  3. PDF

Responses

  1. Submit a response
  2. No responses published

Register for free content

The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.